Palmitoylethanolamide (PEA) is an endogenous fatty acid amide that has been studied for its anti-inflammatory and analgesic properties. Its use for dermatitis is supported by emerging, but limited, scientific evidence. Several small clinical studies and preclinical models have indicated that PEA may help reduce inflammation, itch, and discomfort associated with various forms of dermatitis, including atopic dermatitis. For example, a few randomized controlled trials and observational studies have reported that topical or oral PEA formulations can improve skin barrier function, decrease pruritus (itch), and reduce the severity of dermatitis symptoms. These effects are thought to be mediated via PEA’s modulation of mast cell activity, downregulation of pro-inflammatory cytokines, and enhancement of endogenous cannabinoid signaling pathways, which are involved in skin homeostasis and immune response.

However, the quality and quantity of clinical evidence remain modest. Most studies are small, short-term, and sometimes lack rigorous controls or blinding. There are no large-scale, high-quality randomized controlled trials definitively establishing PEA’s efficacy or safety for dermatitis. As such, while preliminary findings are promising and suggest a plausible scientific rationale for PEA’s use in dermatitis, more robust research is needed before it can be recommended as a mainstream or first-line therapy.